Search

YoungEHA featured in the European Medical Journal!

As part of a series of interviews conducted at this year’s EHA congress in Amsterdam, the European Medical Journal has published their highly insightful discussions with three distinct members: Professor Shai Izraeli, Professor Barbara Bain, and YoungEHA’s very own Dr…

Read more

EHA-ASH Translational Research Training in Hematology

TRTH 2025 call is now closed. What is Translational Research Training in Hematology?Translational Research Training in Hematology (TRTH) provides early-career researchers with a unique, year-long training and mentoring experience.

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

EHA-KCS Hematology Tutorial

EHA is joining the Kazakhstan Cancer Society (KCS) to organize the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more

Highlights of Past EHA (HOPE) Asia 2019

The 1st edition of the Highlights of Past EHA (HOPE) Asia 2019 took place in Kolkata, India. The meeting was organized in partnership with regional and national societies in Asia.

Read more

Myelodysplastic Syndromes (MDS)

The SWG on Myelodysplastic Syndromes (MDS) focuses on the promotion and exchange of scientific and clinical evidence, ideas and projects in the field of MDS.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more